The objective of our study is to provide a comprehensive review of the potential benefits, effectiveness, and safety profile of SGLT-2 inhibitors in HF patients with no history of diabetes mellitus and to summarize the most relevant clinical evidence which supports the rationale for their use in HF patients without T2DM. This evidence concerns the gene SLC5A2 and hydrops fetalis.